Physician profile
Christopher Murphy King
NPI 1750382461
$2,204.62
in general payments reported to CMS, 2019-2025
33 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $223 · 2021: $441 · 2022: $350 · 2023: $289 · 2024: $153 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $330.52 | 2019-2025 | |
| Novo Nordisk INC | $327.67 | 2019-2023 | Rybelsus, Ozempic, Saxenda |
| Lilly USA, LLC | $144.52 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Antares Pharma, INC. | $143.04 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Medtronic Vascular, INC. | $109.20 | 2019 | |
| Amgen INC. | $97.21 | 2019-2023 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $95.63 | 2021-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $92.82 | 2019-2021 | |
| Genentech USA, INC. | $82.20 | 2019-2021 | |
| Bausch Health US, LLC | $75.06 | 2021-2022 | |
| Eisai INC. | $73.39 | 2019-2021 | |
| Allergan, INC. | $63.91 | 2019-2020 | |
| Clarus Therapeutics INC. | $57.91 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.62 | 2019-2024 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $43.19 | 2019-2022 | |
| Pfizer INC. | $40.35 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $39.31 | 2023-2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $38.36 | 2021 | |
| Medtronic, INC. | $32.31 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $29.16 | 2022 | |
| Axonics, INC. | $25.92 | 2023 | Axonics |
| Nestle Healthcare Nutrition INC. | $20.40 | 2020 | |
| Zyla Life Sciences, INC. | $19.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.21 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.18 | 2025 | Jardiance |
| Acella Pharmaceuticals, LLC | $14.60 | 2023 | NP Thyroid 60 |
| Shire North American Group INC | $14.20 | 2019 | |
| Si-Bone, INC. | $12.76 | 2022 | |
| Galderma Laboratories, L.P. | $12.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.79 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.